Engineering the ER Stress Response to Promote the Survival and Cytotoxic Specificity of CAR T cells
Engineering the ER Stress Response to Promote the Survival and Cytotoxic Specificity of CAR T cells
批准号:
10212964
负责人:
Samuel Robert Kerr
金额:
$4.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30
关键词:
Acute Lymphocytic LeukemiaAdoptive Cell TransfersAntibodiesAntigensApoptosisApoptoticB-Cell LeukemiaB-LymphocytesBehavior ControlBindingBiologicalBiologyCD28 geneCD8-Positive T-LymphocytesCD8B1 geneCTLA4 geneCell SurvivalCell membraneCellsCleaved cellCritical PathwaysEngineeringEquilibriumExposure toGenerationsGenetic TranscriptionHumanIn VitroInfectionInflammatoryIntronsIsogenic transplantationLeukocytesLigandsLogicMalignant NeoplasmsMediatingMessenger RNAMusPathway interactionsPatientsPlasma CellsPost-Transcriptional RegulationProteinsRNA SplicingRefractoryRelapseSignal PathwaySignal TransductionSolid NeoplasmSpecificitySpeedStressSurfaceSystemT cell differentiationT-Cell ActivationT-Cell Antigen Receptor SpecificityT-LymphocyteTNFSF10 geneTestingTissuesTranscriptTranscriptional RegulationWorkXBP1 genebiological adaptation to stresscancer cellcancer therapycell killingchimeric antigen receptorchimeric antigen receptor T cellscytotoxiccytotoxicityeffector T cellendoplasmic reticulum stressengineered T cellseosinophilgenetic manipulationimprovedin vivomacrophagemelanomamouse modelneoplastic cellnovelresponsetooltranscription factortumortumor microenvironmenttumor specificitytumor-immune system interactions
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
Chimeric antigen receptor (CAR) T cells have revolutionized cancer therapies and show incredible
responses in patients with relapsed or refractory B cell cancers, yet are ineffective in solid tumors. In order to
work in solid tumors, CAR T cells must be able to survive the immunosuppressive tumor microenvironment
(TME) and distinguish between antigens presented on tumor cells and healthy tissue. Both of these obstacles
can be overcome through clever synthetic engineering of the T cell using known biological circuits. We have
identified a pathway critical to the survival and function of multiple types of leukocytes and naturally turned on
during activation of CD8+ T cells, however surprisingly, it is not activated in the tumor microenvironment. Here,
I propose to synthetically activate this pathway in order to promote CD8+ CAR T cell cytotoxicity and on-target,
on-tumor specificity. Specifically, I will first explore multiple aspects of this signaling pathway and its ability to
promote CAR T cell survival and cytotoxicity under the stresses in the tumor microenvironment. As a second
strategy to improve CAR-T cell specificity for solid tumors, I will engineer a construct that selectively activates a
CAR in response to post-transcriptional regulation. Benefits of post-transcriptional regulation include speed of
activation, and amplification of signal. By making both the post-transcriptional regulator and the target
dependent on binding target cell antigens, I will functionally create an “AND” logic gate, requiring stimulation
from 2 separate antigens in order to facilitate CAR T cell killing. For both strategies I will first demonstrate their
efficacy in vitro with primary mouse and human cells simulating TME conditions, and then in vivo using a
syngeneic transplanted melanoma mouse model. Overall, I hypothesize that synthetic activation of this critical
T cell pathway will enhance CAR-T behavior and control in the solid TME.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文